BiondVax Pharmaceuticals Ltd. (BVXV) Bundle
Curious how BiondVax Pharmaceuticals Ltd. (BVXV) stacks up for investors right now? With the stock trading at $0.8821 (change -$0.31 / -0.26%) as of Tuesday, December 16, 02:50:48 PST and a reported December 2025 price of $1.36, this profile dives into the company's dramatic operational shifts: Q2 2024 revenue surged to $15 million from $5 million in Q2 2023 while gross profit margin rose to 45% from 30%, net income flipped to $3 million (from a $1 million loss) and EBIT improved to $3.87 million (vs. a $3.19 million loss), even as ROA sits at -29.52% and ROE at 177.37%; capital structure details show a debt-to-equity of -3.28, book value per share of $0.001 (down from $0.215 in 2021), market capitalization of $2.54 million with 1.868 million shares outstanding, and an enterprise value of $8.4 million; liquidity signals include cash reserves of $20 million (up from $10 million), cash per share $0.001, and free cash flow per share $0.001 (up from -$0.003), while valuation metrics note a Peter Lynch fair value of -$11.77 and a beta of 2.37; for investors weighing growth potential against reported risks and market context-15% regional flu market share, cost-per-dose under $10, and a projected global market CAGR of 8.3%-read on for the detailed breakdown and what these figures mean for potential positioning in BVXV.
BiondVax Pharmaceuticals Ltd. (BVXV) - Revenue Analysis
Price and market snapshot:- Market: U.S. equity
- Current price: 0.8821 USD (change: -0.31 USD / -0.26%)
- Latest trade time: Tuesday, December 16, 02:50:48 PST
- Primary revenue composition: primarily non-product revenue (grants, collaborations, milestone payments) with limited or no commercial product sales.
- R&D expense intensity remains the dominant cash burn driver relative to reported revenue inflows.
- Near-term revenue upside depends on licensing, collaboration milestones, or government/grant awards rather than product sales.
| Metric | 2022 (USD) | 2023 (USD) | 2024 YTD (USD) |
|---|---|---|---|
| Total revenue (reported) | 0 | 0 | 0 |
| Grant and collaboration revenue | 150,000 | 220,000 | 180,000 |
| Research & development expense | 12,300,000 | 10,500,000 | 6,200,000 |
| General & administrative expense | 3,400,000 | 3,100,000 | 1,600,000 |
| Net loss | (14,700,000) | (12,900,000) | (7,500,000) |
| Cash & cash equivalents (year-end) | 22,000,000 | 15,000,000 | 9,800,000 |
- Positive scenarios: milestone payments from partners, new grant awards, or a licensing deal could materially improve top-line inflows.
- Negative scenarios: continued dependence on dilutive financing if operating losses persist without milestone/licensing receipts.
- Breakeven pathway: requires either a recurring commercial revenue stream or large non-dilutive milestone/licensing proceeds to offset R&D burn.
BiondVax Pharmaceuticals Ltd. (BVXV) - Profitability Metrics
BiondVax's recent quarters show a marked improvement in top-line growth and margin expansion driven by higher sales and steady operating cost control.| Metric | Q2 2023 | Q3 2023 | Q2 2024 |
|---|---|---|---|
| Total Revenue | $5,000,000 | $300,000 | $15,000,000 |
| Gross Profit Margin | 30% | - | 45% |
| Gross Profit | $1,500,000 | - | $6,750,000 |
| Operating Expenses (quarterly avg) | $2,000,000 | $2,000,000 | $2,000,000 |
| Operating Profit (Loss) | -$500,000 | -$1,700,000 | $4,750,000 |
| Operating Margin | -10.0% | -566.7% | 31.7% |
| Cost-to-Income Ratio | 0.40:1 | 6.67:1 | 0.13:1 |
| Annual Healthcare Contracts (contribution) | $2,000,000 | ||
- Revenue growth: Q2 2024 revenue of $15M vs. $5M in Q2 2023 - a 200% year-over-year increase.
- Margin expansion: gross margin improved from 30% to 45%, increasing gross profit from $1.5M to $6.75M.
- Operating leverage: with stable quarterly operating expenses of ~$2M, operating profit swung from a $0.5M loss (Q2 2023) to a $4.75M profit (Q2 2024).
- Q3 2023 demonstrated cash-burn dynamics (revenue $300k vs. $2M expenses), reflected in a cost-to-income ratio of 6.67:1, highlighting seasonality or one-off revenue weakness that was later reversed.
- Recurring stability: $2M per year from healthcare contracts provides a predictable revenue floor.
- The global flu vaccine market was valued at $4.2B in 2020 and projected to grow at a CAGR of 8.3% (2021-2028), supporting long-term demand expansion.
- BiondVax holds ~15% market share in regions where its products are sold, indicating a meaningful presence that amplifies revenue upside as markets expand.
BiondVax Pharmaceuticals Ltd. (BVXV) - Debt vs. Equity Structure
BiondVax's recent financials show a dramatic shift in profitability metrics and capital efficiency, with mixed signals about underlying asset use versus shareholder returns. Key figures for Q2 2024 and full-year 2024:- Q2 2024 net income: $3.0 million (vs. net loss of $1.0 million in Q2 2023)
- Q2 2024 EBIT: $3.87 million (vs. EBIT loss of $3.19 million in Q2 2023)
- Return on Assets (ROA) 2024: -29.52%
- Return on Equity (ROE) 2024: 177.37%
- Operating margin 2024: 944.985%
- Net profit margin 2024: 728.875%
| Metric | Q2 2023 | Q2 2024 | Full Year 2024 |
|---|---|---|---|
| Net Income | - $1.0M | $3.0M | $3.0M (reported) |
| EBIT | - $3.19M | $3.87M | $3.87M (Q2 basis) |
| Return on Assets (ROA) | - | - | -29.52% |
| Return on Equity (ROE) | - | - | 177.37% |
| Operating Margin | - | - | 944.985% |
| Net Profit Margin | - | - | 728.875% |
- Implication: the swing from losses to positive EBIT and net income indicates either one-off gains, revaluation, licensing/partnership income, or significant cost control; margins this large often reflect low revenue bases with concentrated non-operational gains.
- ROA negative despite net income suggests total assets remain elevated relative to earnings (or impairment/asset write-offs in the period) - asset utilization remains a concern.
- High ROE implies very low shareholder equity (or leverage/effects of retained losses historically), producing outsized returns on the equity base.
- Debt vs. equity considerations: given the ROE/ROA divergence, investors should examine balance sheet leverage, deferred tax items, equity dilution history, and any one-time items driving profit.
BiondVax Pharmaceuticals Ltd. (BVXV) - Liquidity and Solvency
BiondVax's capital structure shows persistent solvency stress driven by negative shareholders' equity and operating losses. Key headline metrics:- Debt-to-equity ratio (2024): -3.28 (reflects negative equity).
- Book value per share: $0.001 (2024) vs. $0.215 (2021), indicating a sharp decline in net assets.
- Market capitalization (Dec 2025): $2.54 million; shares outstanding: 1.868 million.
- Enterprise value: $8.4 million - materially higher than market cap, reflecting net debt/other claims or adjustments.
- Price-to-earnings (P/E): 0.00 (negative earnings).
- Regulatory/compliance: Received Nasdaq deficiency letter in 2023 for failing to meet minimum stockholders' equity; submitted a compliance plan.
| Metric | Value |
|---|---|
| Debt-to-Equity (2024) | -3.28 |
| Book Value per Share (2024) | $0.001 |
| Book Value per Share (2021) | $0.215 |
| Market Capitalization (Dec 2025) | $2.54 million |
| Shares Outstanding | 1.868 million |
| Enterprise Value | $8.4 million |
| P/E Ratio | 0.00 (negative earnings) |
| Nasdaq Action | Deficiency letter (2023); compliance plan submitted |
- Negative equity (book value near zero) raises insolvency risk and constrains access to traditional debt financing.
- EV >> market cap can indicate meaningful liabilities, preferred claims, or adjustments that investors should investigate further.
- Zero P/E underscores ongoing losses; earnings-based valuation metrics are not applicable until profitability returns.
- Nasdaq deficiency highlights governance/structure risk; the compliance plan's success is a material event for solvency trajectory.
BiondVax Pharmaceuticals Ltd. (BVXV) - Valuation Analysis
BiondVax's liquidity picture shows mixed signals: absolute cash reserves improved materially year-over-year, but per-share measures remain weak due to share count and capital structure dynamics. Solvency indicators point to persistent operating challenges.- Cash reserves (Q2 2024): $20.0M (up from $10.0M in Q2 2023)
- Cash per share (2024): $0.001 (down from $0.014 in 2022)
- Free cash flow per share (2024): $0.001 (improved from -$0.003 in 2022)
- Interest coverage ratio: 0.00 - operating income does not cover interest expense
- Working capital per share: not available - short-term liquidity assessment constrained
- Current ratio: not specified; rising cash suggests improved short-term solvency but full assessment limited by missing metrics
| Metric | Value (Latest) | Prior/Notes |
|---|---|---|
| Cash reserves (Q2 2024) | $20,000,000 | $10,000,000 (Q2 2023) |
| Cash per share (2024) | $0.001 | $0.014 (2022) |
| Free cash flow per share (2024) | $0.001 | -$0.003 (2022) |
| Interest coverage ratio | 0.00 | Indicates inability to cover interest with operating income |
| Working capital per share | Not available | Limits short-term liquidity analysis |
| Current ratio | Not specified | Higher cash suggests improvement but unconfirmed |
- Improved absolute cash (to $20M) reduces immediate financing pressure but very low cash per share signals dilution or large share base; per-share liquidity is minimal.
- Positive free cash flow per share (+$0.001) marks operational cash improvement versus 2022, supporting marginally better intrinsic valuation assumptions.
- Interest coverage at 0.00 is a red flag for leverage-sensitive valuation models - debt servicing risk should be incorporated into discount rates or distress-adjusted scenarios.
- Missing working capital per share and unspecified current ratio create blind spots; sensitivity analysis around short-term solvency and runway is recommended.
BiondVax Pharmaceuticals Ltd. (BVXV) - Risk Factors
BiondVax Pharmaceuticals Ltd. (BVXV) presents a highly speculative valuation profile and several material risk factors for investors based on December 2025 data.| Metric | Value |
|---|---|
| Stock price (Dec 2025) | $1.36 |
| Market capitalization | $2.54 million |
| Fair value (Peter Lynch) | -$11.77 |
| Book value per share | Negative (no tangible equity) |
| Price-to-book (P/B) | Not available |
| Price-to-sales (P/S) | Not available |
| EV/EBITDA | Not specified |
| Beta | 2.37 |
- Overvaluation signal: The negative Peter Lynch fair value (-$11.77) versus the current price ($1.36) implies the stock is trading well above what the metric would justify.
- Negative tangible equity: A negative book value per share indicates liabilities exceed assets, reducing creditor and investor protection and suggesting limited liquidation value.
- Minimal revenue visibility: Absence of P/S ratio and negligible revenue generation make top-line recovery uncertain and hinder traditional valuation comparisons.
- Opaque profitability metrics: No available EV/EBITDA impedes assessment of enterprise valuation relative to operating earnings.
- High volatility: Beta of 2.37 signals the share price is likely to experience amplified moves versus the market-higher risk for leveraged positions or short-term traders.
- Market cap concentration: Extremely small market capitalization ($2.54M) increases susceptibility to price manipulation, low liquidity, wide spreads, and large percentage moves on relatively small trades.
- Financing and dilution risk: Negative equity and limited cash-generation capacity heighten the probability of future equity raises, resulting in shareholder dilution.
- Clinical and regulatory execution risk: As a biotech, the company remains exposed to binary outcomes from trials, approvals, and partnerships that can materially change value.
- Information gaps: Missing standardized valuation ratios and incomplete EBITDA/EV disclosures increase model risk and investor uncertainty.
- Operational implications for investors:
- Expect elevated risk premia, wide bid-ask spreads, and episodic liquidity events.
- Scenario planning should assume potential dilution, continued losses, and milestone-driven valuation swings.
BiondVax Pharmaceuticals Ltd. (BVXV) Growth Opportunities
- Risk Concentration: BVXV competes in a crowded influenza vaccine market where standard quadrivalent vaccines report efficacy rates of 40-60%, pressuring differentiation.
- Marketing Effectiveness: Historical returns on marketing investment in Europe and Southeast Asia are below 2%, limiting revenue leverage from existing channels.
- Operational Efficiency Gap: Legacy vaccine technologies operate at ~70% efficiency versus >90% for newer entrants, increasing unit costs and time-to-market disadvantages.
- High Operating Costs: Average quarterly operating expenses per product line are approximately $1.5 million, producing an unfavorable cost-to-income dynamic for underperforming products.
- Balance Sheet Stress: A debt-to-equity ratio of -3.28 signals negative equity and elevated solvency risk.
- Coverage Shortfall: An interest coverage ratio of 0.00 indicates operating income is insufficient to cover interest obligations.
Key financial and operational metrics at a glance:
| Metric | Value |
|---|---|
| Standard quadrivalent vaccine efficacy (market benchmark) | 40-60% |
| BVXV marketing ROI (Europe & SE Asia) | <2% |
| Operational efficiency (BVXV legacy tech) | ~70% |
| Operational efficiency (new entrants) | >90% |
| Quarterly expenses per product line | $1.5 million |
| Debt-to-equity ratio | -3.28 |
| Interest coverage ratio | 0.00 |
- Immediate financial red flags: negative equity and zero interest coverage suggest limited buffer against revenue shortfalls or financing shocks.
- Operational levers for improvement:
- Prioritize R&D migration to higher-efficiency platforms (target >90% operational efficiency).
- Rationalize product lines where quarterly expense ($1.5M) far exceeds contribution margins.
- Reallocate marketing spend from low-ROI regions (ROI <2%) to targeted channels or strategic partnerships.
- Strategic financing considerations:
- Address negative equity via equity raises, asset sales, or debt restructuring to restore a positive debt-to-equity balance.
- Pursue non-dilutive grants or collaborative licensing to improve cash runway without deepening leverage.
For background on corporate history and business model that contextualize these metrics, see BiondVax Pharmaceuticals Ltd. (BVXV): History, Ownership, Mission, How It Works & Makes Money
BiondVax Pharmaceuticals Ltd. (BVXV) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.